top of page
mHeart-Logo.png
DRS.LINQ is redefining cardiac care with mHeart, a first-of-its-kind mobile platform that combines a self-administered 10-lead multiparametric EKG device with a robust remote management system. Designed by cardiologists for cardiologists and patients, mHeart enables rapid triage, biweekly monitoring, and long-term cardiac management — improving outcomes, reducing healthcare costs, and empowering patients through early intervention and real-time physician connectivity.

Lead Program & Pipeline

  • Lead product: mHeart — a mobile EKG-enabled care platform for acute and chronic cardiac management

  • Includes 10-lead self-administered EKG and a remote management interface

  • Aims to reduce ER visits, hospital readmissions, and cardiac-related mortality

  • Targeting use in post-operative care, chronic condition monitoring, and chest pain triage

  • Future pipeline includes predictive AI/ML algorithms for risk stratification and personalized care

Technology Differentiators

  • Combines FDA-cleared 10-lead EKG hardware with remote software platform

  • Enables patient-initiated triage within 15 minutes of symptom onset

  • Supports physicians with reimbursable telehealth services and real-time cardiac data

  • Collects biweekly EKGs to build a longitudinal cardiac profile

  • Designed to reduce unnecessary ER visits and improve heart failure, AFib, and ACS outcomes

Stage & Investment

  • Stage: Product development (Gen 1 hardware & software in progress)

  • Funding Raised: <$500K

  • IP: Utility patent in process; design patents filed (US, Canada, EU); future patents for software/AI planned

  • Regulatory: 510(k) path confirmed by FDA for hardware; SaMD submission planned post-data collection

  • Collaborations: LOI in progress with Atrial Health; early discussions with Cleveland Clinic, Capital Health, and Mount Sinai

What's Next

  • Complete Gen 1 software (6 months) and hardware (12 months)

  • Conduct clinical data collection and submit for 510(k) (12–14 months)

  • Achieve FDA clearance (16–18 months)

  • Expand team, customer outreach, and prepare for manufacturing and commercialization

  • Secure funding and strategic partners to position mHeart as a category-defining digital health platform

Leadership

Rakesh-Shah-Headshot-Web-002.png
Rakesh Shah, MD, MBA, FACC
Founder/CMO
1565720974243.jpg
Jerry Ruddle, MBA
CEO
bottom of page